Los Angeles Capital Management LLC Purchases 157,575 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Los Angeles Capital Management LLC boosted its position in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 45.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 500,567 shares of the company’s stock after acquiring an additional 157,575 shares during the quarter. Los Angeles Capital Management LLC owned 0.38% of Organogenesis worth $1,422,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Palumbo Wealth Management LLC acquired a new stake in Organogenesis in the fourth quarter valued at approximately $46,000. Capital Square LLC boosted its position in Organogenesis by 23.8% in the fourth quarter. Capital Square LLC now owns 20,450 shares of the company’s stock valued at $84,000 after buying an additional 3,930 shares in the last quarter. Swiss National Bank acquired a new stake in Organogenesis in the third quarter valued at approximately $505,000. SG Americas Securities LLC boosted its position in Organogenesis by 23.2% in the fourth quarter. SG Americas Securities LLC now owns 35,774 shares of the company’s stock valued at $146,000 after buying an additional 6,727 shares in the last quarter. Finally, Bailard Inc. acquired a new stake in Organogenesis in the fourth quarter valued at approximately $147,000. 49.57% of the stock is owned by institutional investors.

Organogenesis Price Performance

Organogenesis stock opened at $2.50 on Friday. Organogenesis Holdings Inc. has a 52 week low of $1.96 and a 52 week high of $4.70. The company’s 50 day moving average price is $2.65 and its two-hundred day moving average price is $3.14. The stock has a market cap of $331.43 million, a P/E ratio of 62.52 and a beta of 1.66. The company has a quick ratio of 2.41, a current ratio of 2.74 and a debt-to-equity ratio of 0.22.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Organogenesis had a return on equity of 2.11% and a net margin of 1.34%. The company had revenue of $109.98 million for the quarter, compared to analysts’ expectations of $100.44 million. During the same period in the previous year, the business posted ($0.02) EPS. On average, equities analysts predict that Organogenesis Holdings Inc. will post -0.05 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $5.00 price target on shares of Organogenesis in a report on Friday, March 1st.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.